MoneyInvestor's Business Daily
AbbVie Partner Flies Sky-High On News For Its $3 Billion Cancer Contender
The addition of Genmab's Epkinly to a standard cocktail of drugs helped lymphoma patients live longer before worsening. Genmab stock rocketed. The post AbbVie Partner Flies Sky-High On News For Its $3 Billion Cancer Contender appeared first on Investor's Business Daily.
Join the argument
House rules →Comments load as you scroll.